Asset Details
Do you wish to reserve the book?
Identification of compounds that suppress Toxoplasma gondii tachyzoites and bradyzoites
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Identification of compounds that suppress Toxoplasma gondii tachyzoites and bradyzoites
Do you wish to request the book?
Identification of compounds that suppress Toxoplasma gondii tachyzoites and bradyzoites
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Identification of compounds that suppress Toxoplasma gondii tachyzoites and bradyzoites
2017
Overview
Drug treatment for toxoplasmosis is problematic, because current drugs cannot eradicate latent infection with Toxoplasma gondii and can cause bone marrow toxicity. Because latent infection remains after treatment, relapse of infection is a problem in both infections in immunocompromised patients and in congenitally infected patients. To identify lead compounds for novel drugs against Toxoplasma gondii, we screened a chemical compound library for anti-Toxoplasma activity, host cell cytotoxicity, and effect on bradyzoites. Of 878 compounds screened, 83 demonstrated >90% parasite growth inhibition. After excluding compounds that affected host cell viability, we further characterized two compounds, tanshinone IIA and hydroxyzine, which had IC50 values for parasite growth of 2.5 μM and 1.0 μM, respectively, and had no effect on host cell viability at 25 μM. Both tanshinone IIA and hydroxyzine inhibited parasite replication after invasion and both reduced the number of in vitro-induced bradyzoites, whereas, pyrimethamine, the current therapy, had no effect on bradyzoites. Both tanshinone IIA and hydroxyzine are potent lead compounds for further medicinal chemistry. The method presented for evaluating compounds for bradyzoite efficacy represents a new approach to the development of anti-Toxoplasma drugs to eliminate latency and treat acute infection.
Publisher
Public Library of Science,Public Library of Science (PLoS)
Subject
/ Antiprotozoal Agents - chemistry
/ Antiprotozoal Agents - isolation & purification
/ Antiprotozoal Agents - pharmacology
/ Diterpenes, Abietane - chemistry
/ Diterpenes, Abietane - pharmacology
/ Drugs
/ Host-Parasite Interactions - drug effects
/ Humans
/ Kinases
/ Latency
/ Medicine and Health Sciences
/ Patients
/ Protozoa
/ Pyrimethamine - pharmacology
/ Research and Analysis Methods
/ Therapy
/ Toxicity
/ Toxoplasmosis - drug therapy
/ Toxoplasmosis - parasitology
/ Toxoplasmosis, Animal - drug therapy
